

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

### **翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

## **VOLUNTARY ANNOUNCEMENT LICENSING AGREEMENT WITH QYUNS**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on April 24, 2024, Hansoh (Shanghai) Healthtech Company Limited \* (翰森(上海)健康科技有限公司) (the “**Licensee**”), a wholly-owned subsidiary of the Company, entered into a license agreement (the “**Licensing Agreement**”) with Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司) (“**Qyuns**”).

Pursuant to the Licensing Agreement, the Licensee obtained an exclusive license from Qyuns to develop and commercialize Monoclonal Antibody QX004N (“**QX004N**”) within China (including Hong Kong, Macau and Taiwan). The Licensee will be responsible for the research and development (“**R&D**”), manufacturing and commercialization of QX004N in all developable dosage forms and indications in China, and will pay an upfront payment of RMB75 million and potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB1,032 million, plus tiered royalties on future product sales.

### **ABOUT QX004N**

QX004N is an innovative drug candidate indicated for psoriasis and Crohn’s disease. As of the date of this announcement, QX004N has been initiated in various clinical studies, with the highest stage of development in China being a Phase II clinical trial.

### **ABOUT QYUNS**

Founded in 2015 and listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in March 2024 (Stock Code: 02509.HK), Qyuns is a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases. To the best knowledge and belief of the Company, Qyuns is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

## LISTING RULES IMPLICATIONS

The upfront payment of RMB75 million is expected to be recognized as R&D expenditure of the Company. Assuming that the transactions contemplated under the Licensing Agreement constitute “transactions” for the purpose of Chapter 14 of the Listing Rules, as all the applicable percentage ratios in respect of the remaining potential payments under the Licensing Agreement are below 5%, the transactions contemplated under the Licensing Agreement do not constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules. Furthermore, the transactions contemplated under the Licensing Agreement do not constitute any connected transactions of the Company under Chapter 14A of the Listing Rules.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, April 25, 2024

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* *For identification purposes only*